[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100658827":3},{"organization":4,"outcomesModule":7,"designInfo":23,"detailedDescription":27,"studyPopulation":28,"armGroups":29,"interventions":35,"overallOfficials":24,"centralContacts":41,"locations":47,"responsibleParty":64,"collaborators":24,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":69,"sex":75,"minAge":76,"maxAge":24,"enrollmentInfo":77,"targetDuration":80,"studyType":81,"phases":24,"briefSummary":82,"conditions":83,"keywords":86,"overallStatus":50,"whyStopped":24,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"Istanbul Saglik Bilimleri University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":18},[9],{"measure":10,"description":11,"timeFrame":12},"Change in SARC-F (Strength, Assistance in walking, Rise from a chair, Climb stairs, and Falls) total score","SARC-F is a 5-item sarcopenia screening questionnaire. Total score ranges from 0 to 10, and higher scores indicate a worse outcome (greater risk of sarcopenia). Change = month 3 score minus baseline score, reported in points on the scale.","Baseline (GLP-1 RA initiation) and 3 months",[14],{"measure":15,"description":16,"timeFrame":17},"Number of participants with a positive SARC-F screening result","Positive screening is defined as a SARC-F total score of 4 or higher (scale range 0 to 10; higher scores indicate a worse outcome). Reported as number of participants.","Baseline and 3 months",[19],{"measure":20,"description":21,"timeFrame":22},"Change in handgrip strength","Maximum handgrip strength in kilograms, measured with a hydraulic hand dynamometer (seated, elbow at 90°, three trials per hand; highest of six values used). Change = month 3 minus baseline. Higher values indicate greater strength (better outcome).","baseline and 3 months.",{"allocation":24,"interventionModel":24,"interventionModelDescription":24,"primaryPurpose":24,"observationalModel":25,"timePerspective":26,"maskingInfo":24},null,"COHORT","PROSPECTIVE","Adults aged 18 years or older with obesity (BMI \\>30 kg\u002Fm²) and without diabetes, who are referred from the Endocrinology and Metabolism and Internal Medicine outpatient clinics to the Diabetes Education Unit and are receiving a GLP-1 RA for its approved indication, will be enrolled after verbal consent. Sarcopenia screening uses the SARC-F questionnaire (strength, assistance in walking, rise from a chair, climb stairs). Muscle strength and performance are assessed by handgrip strength (hydraulic hand dynamometer, seated, elbow at 90°, three trials per hand, highest value recorded, population-specific EWGSOP2 cut-offs), the five-times chair stand test (\\>15 seconds indicates high risk) and 4-metre gait speed (\\\u003C0.8 m\u002Fs indicates low performance). Skeletal muscle mass index (SMMI), BMI and fat mass are obtained by bioelectrical impedance analysis (BIA), which is already performed at every routine follow-up visit. Routine laboratory results are transcribed from clinical records; no additional blood samples are requested. Assessments occur at GLP-1 RA initiation and at month 3.","Adults with obesity and no diabetes referred from the Endocrinology and Metabolism and Internal Medicine outpatient clinics to the Diabetes Education Unit and using a GLP-1 RA.",[30],{"label":31,"type":24,"description":32,"interventionNames":33},"Non-diabetic obese adults receiving a GLP-1 RA (or GLP-1\u002FGIP dual agonist) for obesity","Adults (≥18 years) with BMI ≥30 kg\u002Fm² and no diabetes who start GLP-1 RA treatment under routine clinical care and are followed at the Diabetes Education Unit.",[34],"Drug: GLP-1 receptor agonist (e.g., semaglutide, tirzepatide) - prescribed by the treating physician as standard care; the study does not assign or alter treatment.",[36],{"type":37,"name":38,"description":39,"armGroupLabels":40,"otherNames":24},"DRUG","GLP-1 receptor agonist (e.g., semaglutide, tirzepatide) - prescribed by the treating physician as standard care; the study does not assign or alter treatment.","GLP-1 receptor agonist (GLP-1 RA) or dual GLP-1\u002FGIP receptor agonist (e.g., semaglutide, tirzepatide) prescribed by the treating physician as routine clinical care for obesity in adults without diabetes. The agent, dose and duration are determined by the treating physician; the study does not assign, supply or modify treatment. Participants are enrolled at GLP-1 RA initiation and followed for 3 months at the Diabetes Education Unit. Study-specific assessments at baseline and month 3: SARC-F questionnaire, handgrip strength (hydraulic dynamometer), five-times chair stand test and 4-metre gait speed. Body composition by bioelectrical impedance analysis (skeletal muscle mass index, fat mass) and routine laboratory results are taken from standard clinical follow-up; no additional blood tests are requested.",[31],[42],{"name":43,"role":44,"phone":45,"phoneExt":24,"email":46},"GÜLDEN ANATACA","CONTACT","05059284244","ganataca@yahoo.com",[48],{"facility":49,"status":50,"city":51,"state":52,"zip":24,"country":53,"countryCode":24,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"Kanuni Sultan Süleyman Training and Research Hospital","RECRUITING","Istanbul","Kucukcekmece","Turkey (Türkiye)",{"type":55,"coordinates":56},"Point",[57,58],28.94966,41.01384,{"lat":58,"lon":57},[61],{"name":62,"role":44,"phone":63,"phoneExt":24,"email":46},"gülden ANATACA","5059284244",{"type":65,"investigatorFullName":43,"investigatorTitle":66,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"PRINCIPAL_INVESTIGATOR","MsD","100658827","glp-1-receptor-agonist-use-and-sarcopenia-in-obese-individuals-without-diabetes-100658827",false,"NCT07858864","GLP-1 Receptor Agonist Use and Sarcopenia in Obese Individuals Without Diabetes","Evaluation of the Relationship Between GLP-1 Receptor Agonist Use and Sarcopenia in Non-Diabetic Obese Individuals: A Prospective Descriptive Study","GLP1-SARCO","Inclusion Criteria:\n\n* Age 18 years or older\n* Diagnosis of obesity (BMI \\>30 kg\u002Fm²)\n* Currently using a GLP-1 RA\n* No hearing, speech or cognitive impairment\n* Not receiving treatment for major depressive disorder and not using antidepressants\n* Verbal consent to participate\n\nExclusion Criteria:\n\n* Diagnosis of diabetes\n* History of chronic kidney failure, chronic liver disease, decompensated heart failure or malignancy\n* Pregnancy or breastfeeding\n* Walking impairment\n* Not meeting inclusion criteria or unwilling to participate","ALL","18 Years",{"count":78,"type":79},42,"ESTIMATED","3 Months","OBSERVATIONAL","Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual GLP-1\u002FGIP agonists such as semaglutide and tirzepatide produce marked weight loss in people with obesity, with reported reductions of about 15-20%. Rapid weight loss may reduce not only fat mass but also lean body mass and skeletal muscle mass, raising concern about sarcopenia and sarcopenic obesity. Evidence in non-diabetic obese individuals is limited and inconsistent. This prospective descriptive study will assess muscle mass, muscle strength, physical performance and sarcopenia risk in non-diabetic obese adults starting GLP-1 RA therapy, at baseline and at month 3, and will examine how weight loss relates to changes in body composition.",[84,85],"Obesity","Sarcopenia",[87,85,88,89],"GLP-1 receptor agonist","Sarcopenic obesity","SARC-F Handgrip strength","2026-10-05",{"date":92,"type":93},"2026-10-08","ACTUAL",{"date":95,"type":93},"2026-05-30",{"date":97,"type":79},"2026-11-30",{"name":5,"class":6},1]